IDEXX Laboratories Inc., commonly known as IDEXX, is a prominent player in the development, manufacture, and distribution of diagnostic and information management products for the companion animal, livestock, and poultry industries. The company was established in Delaware in 1983 and is publicly traded on the NASDAQ stock exchange under the symbol IDXX. IDEXX operates its business through three primary segments: the Companion Animal Group, Water Quality Products, and Livestock, Poultry, and Dairy. The company's offerings are geared towards improving...
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | TMO | Thermo Fisher Scientific Inc. | 216.83 Bn | 33.00 | 4.96 | 35.68 Bn |
| 2 | DHR | Danaher Corp /De/ | 162.47 Bn | 46.38 | 6.69 | 16.86 Bn |
| 3 | IDXX | Idexx Laboratories Inc /De | 56.88 Bn | 55.36 | 13.65 | 1.09 Bn |
| 4 | A | Agilent Technologies, Inc. | 39.82 Bn | 32.64 | 5.87 | 3.41 Bn |
| 5 | IQV | Iqvia Holdings Inc. | 38.85 Bn | 30.28 | 2.44 | 15.19 Bn |
| 6 | NTRA | Natera, Inc. | 31.32 Bn | -101.29 | 14.80 | 0.18 Bn |
| 7 | MTD | Mettler Toledo International Inc/ | 28.99 Bn | 34.68 | 7.35 | 2.21 Bn |
| 8 | WAT | Waters Corp /De/ | 22.92 Bn | 35.32 | 7.38 | 1.49 Bn |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| EV to Assets | 17.10 | 2.69 | |
| EV to Cash from Ops. | 53.24 | 18.14 | |
| EV to Debt | 53.32 | 52.51 | |
| EV to EBIT | 44.19 | 19.22 | |
| EV to EBITDA | 40.05 | 4.35 | |
| EV to Free Cash Flow [EV/FCF] | 60.75 | 2.84 | |
| EV to Market Cap | 1.02 | 1.52 | |
| EV to Revenue | 13.90 | 4.79 | |
| Price to Book Value [P/B] | 36.43 | 1.34 | |
| Price to Earnings [P/E] | 55.36 | 22.02 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| Dividend Coverage Ratio | 0.00 | -1.96 | |
| Dividend Payout Ratio % | 0.00 | 2.83 | |
| Dividend per Basic Share | 0.00 | 0.19 | |
| FCF Dividend Payout Ratio % | 0.00 | 1.92 | |
| Interest Coverage | 35.29 | -126.58 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| Capex Growth (1y) % | -8.27 | -31.50 | |
| Cash and Equivalents Growth (1y) % | -32.55 | 21.37 | |
| Dividend Growth (1y) % | 0.00 | 0.24 | |
| EBIAT Growth (1y) % | 18.49 | -55.24 | |
| EBITDA Growth (1y) % | 16.83 | -447.96 | |
| EBIT Growth (1y) % | 16.40 | -40.50 | |
| EBT Growth (1y) % | 16.51 | -70.94 | |
| EPS Growth (1y) % | 21.49 | -70.02 | |
| FCF Growth (1y) % | 20.31 | 56.33 | |
| Gross Profit Growth (1y) % | 10.18 | 185.11 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| Asset Utilization Ratio | 1.23 | 0.56 | |
| Cash Payout Ratio | 0.00 | 0.01 | |
| Cash Ratio | 0.17 | 1.21 | |
| Current Ratio | 1.18 | 2.64 | |
| Debt to Equity Ratio | 0.70 | -0.80 | |
| Interest Cover Ratio | 35.29 | -126.58 | |
| Times Interest Earned | 35.29 | -126.58 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| EBITDA Margin % | 34.80 | -129.91 | |
| EBIT Margin % | 31.45 | -156.71 | |
| EBT Margin % | 30.56 | -162.23 | |
| Gross Margin % | 61.70 | 47.70 | |
| Net Profit Margin % | 24.70 | -189.30 |